Elevated levels of Endothelial cell-derived microparticles following short-term withdrawal of continuous positive airway pressure in patients with obstructive sleep apnea: Data from a randomized controlled trial by Ayers, Lisa et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Elevated levels of Endothelial cell-derived microparticles following
short-term withdrawal of continuous positive airway pressure in patients
with obstructive sleep apnea: Data from a randomized controlled trial
Ayers, Lisa; Stoewhas, Anne-Christin; Ferry, Berne; Stradling, John; Kohler, Malcolm
Abstract: Background: Obstructive sleep apnea has been associated with impaired endothelial function;
however, the mechanisms underlying this association are not completely understood. Cell-derived mi-
croparticles may provide a link between obstructive sleep apnea and endothelial dysfunction. Objectives:
This randomized controlled trial aimed to examine the effect of a 2-week withdrawal of continuous positive
airway pressure (CPAP) therapy on levels of circulating microparticles. Methods: Forty-one obstructive
sleep apnea patients established on CPAP treatment were randomized to either CPAP withdrawal (sub-
therapeutic CPAP) or continuing therapeutic CPAP, for 2 weeks. Polysomnography was performed and
circulating levels of microparticles were analyzed by flow cytometry at baseline and 2 weeks. Results:
CPAP withdrawal led to a recurrence of obstructive sleep apnea. Levels of CD62E+ endothelium-derived
microparticles increased significantly in the CPAP withdrawal group compared to the continuing thera-
peutic CPAP group (median difference in change +32.4 per µl; 95% CI +7.3 to +64.1 per µl, p = 0.010).
CPAP withdrawal was not associated with a statistically significant increase in granulocyte, leukocyte,
and platelet-derived microparticles when compared with therapeutic CPAP. Conclusions: Short-term
withdrawal of CPAP therapy leads to a significant increase in endothelium-derived microparticles, sug-
gesting that microparticle formation may be causally linked to obstructive sleep apnea and may promote
endothelial activation.
DOI: 10.1159/000342877
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-69889
Published Version
Originally published at:
Ayers, Lisa; Stoewhas, Anne-Christin; Ferry, Berne; Stradling, John; Kohler, Malcolm (2013). Elevated
levels of Endothelial cell-derived microparticles following short-term withdrawal of continuous positive
airway pressure in patients with obstructive sleep apnea: Data from a randomized controlled trial. Res-
piration, 85(6):478-485. DOI: 10.1159/000342877
E-Mail karger@karger.com
www.karger.com/res
 Clinical Investigations 
 Respiration 2013;85:478–485 
 DOI: 10.1159/000342877 
 Elevated Levels of Endothelial Cell-Derived 
Microparticles following Short-Term Withdrawal 
of Continuous Positive Airway Pressure in
Patients with Obstructive Sleep Apnea:
Data from a Randomized Controlled Trial 
 Lisa Ayers a    Anne-Christin Stoewhas c    Berne Ferry a    John Stradling b    
Malcolm Kohler c, d  
 a  Department of Clinical Immunology and  b  Sleep Unit, Oxford Centre for Respiratory Medicine, Churchill Hospital, 
 Oxford , UK;  c  Sleep Disorders Centre and Pulmonary Division, University Hospital Zurich, and  d  Centre for Integrative 
Human Physiology, University of Zurich,  Zurich , Switzerland 
increased significantly in the CPAP withdrawal group com-
pared to the continuing therapeutic CPAP group (median 
difference in change +32.4 per   l; 95% CI +7.3 to +64.1 per 
  l, p = 0.010). CPAP withdrawal was not associated with a 
statistically significant increase in granulocyte, leukocyte, 
and platelet-derived microparticles when compared with 
therapeutic CPAP.  Conclusions: Short-term withdrawal of 
CPAP therapy leads to a significant increase in endothelium-
derived microparticles, suggesting that microparticle forma-
tion may be causally linked to obstructive sleep apnea and 
may promote endothelial activation.  
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Obstructive sleep apnea (OSA) is characterized by re-
petitive apneas/hypopneas during sleep, associated with 
oxygen desaturations and arousals from sleep. It has been 
estimated that between 2 and 4% of the adult population 
in Western countries suffers from symptomatic OSA syn-
drome (OSAS), and it is becoming more prevalent as the 
average population body weight rises  [1] . OSAS can be ef-
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 Abstract 
 Background: Obstructive sleep apnea has been associated 
with impaired endothelial function; however, the mecha-
nisms underlying this association are not completely under-
stood. Cell-derived microparticles may provide a link be-
tween obstructive sleep apnea and endothelial dysfunction. 
 Objectives: This randomized controlled trial aimed to exam-
ine the effect of a 2-week withdrawal of continuous positive 
airway pressure (CPAP) therapy on levels of circulating mi-
croparticles.  Methods: Forty-one obstructive sleep apnea 
patients established on CPAP treatment were randomized to 
either CPAP withdrawal (subtherapeutic CPAP) or continuing 
therapeutic CPAP, for 2 weeks. Polysomnography was per-
formed and circulating levels of microparticles were ana-
lyzed by flow cytometry at baseline and 2 weeks.  Results: 
CPAP withdrawal led to a recurrence of obstructive sleep ap-
nea. Levels of CD62E+ endothelium-derived microparticles 
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fectively treated with continuous positive airway pressure 
(CPAP).
 OSAS is associated with daytime sleepiness and in-
creased risk of traffic accidents  [2] . Cross-sectional and 
prospective studies have implicated OSA as an important 
causal factor in cardiovascular disease  [3–6] . The link be-
tween OSA and cardiovascular disease is not fully under-
stood; however, it is thought that the physiological conse-
quences of OSA, including intermittent hypoxia and in-
trathoracic pressure changes and arousals, can all result 
in endothelial dysfunction and ultimately arterial disease 
 [7] . Endothelial dysfunction has been shown to improve 
following CPAP therapy  [8–10] . Despite the physiological 
benefits achieved by CPAP therapy, adherence can be 
poor, with many patients choosing to withdraw from 
treatment due to side effects, problems with the device, or 
no perceived benefit  [11] .
 Circulating cell-derived microparticles (MPs) origi-
nate from the plasma membrane of activated or apop-
totic cells, including platelets, leukocytes, and endothe-
lial cells. Although once thought to be inert cellular dust, 
they are now understood to be involved in the pathogen-
esis of vascular inflammation, thrombosis, and endothe-
lial dysfunction, all important processes in cardiovascu-
lar disease  [12] . MPs are elevated in patients with cardio-
vascular risk factors, and they have been shown to predict 
subclinical atherosclerosis in asymptomatic patients  [13] . 
 There is preliminary data from case-control studies 
that MP levels are increased in patients with OSA, and 
that CPAP therapy may lower these levels  [14–17] . How-
ever, there is no data from randomized controlled trials 
proving a causal relationship between OSA and increased 
levels of MPs. We hypothesize that withdrawal from 
CPAP therapy may lead to an increase in MP levels. We 
have taken advantage of a novel CPAP withdrawal ran-
domized controlled study investigating the effects of a 
return of OSA on various outcomes  [18] to explore the ef-
fects of CPAP on MP levels.
 Methods and Materials 
 Patients and Study Design 
 Patients previously diagnosed with OSAS and treated with 
CPAP who were registered in a database of the Sleep Disorders 
Centre and Pulmonary Division of the University Hospital of Zu-
rich, Switzerland, were eligible for the trial if they were aged be-
tween 20 and 75 years, had an oxygen desaturation index (ODI, 
 6 4% dips) of more than 10/h in their initial sleep study, had an 
ODI  1 10/h currently during an ambulatory nocturnal pulse ox-
imetry study (Pulsox-300i; Minolta, Osaka, Japan) performed at 
the end of a 4-night period without CPAP, and if they had been 
treated with CPAP for more than 12 months with a minimal aver-
age compliance of 4 h per night. 
 Patients previously diagnosed with ventilatory failure, Cheyne-
Stokes breathing, unstable and untreated coronary or peripheral 
artery disease, severe and inadequately controlled arterial hyper-
tension, or a history of any sleep-related accident or who were cur-
rent professional drivers were excluded from the study. The trial 
was approved by the University Hospital of Zurich research ethics 
committee (EK-1600) and registered (www.controlled-trials.com, 
ISRCTN 93153804). Written informed consent was obtained from 
all participants. The full methods and the results on the primary 
outcomes (measures of sleep-disordered breathing) and on some 
of the secondary outcomes (such as sleepiness, blood pressure, 
heart rate, endothelial function, and markers of inflammation and 
metabolism) have been described elsewhere  [18] .
 After confirming the persistence of OSA by home overnight 
pulse oximetry on the last night of a 4-night period without CPAP, 
eligible patients returned to therapy with CPAP for at least 1 week. 
After a baseline sleep study on CPAP, patients were randomized 
in a double blind fashion to either continue with CPAP therapy or 
switch to subtherapeutic CPAP for 2 weeks. Follow-up sleep stud-
ies were performed at 2 weeks. 
 Sleep Studies and CPAP 
 Attended polysomnographic sleep studies were performed 
and analyzed according to standard methods. Apnea were de-
fined as a reduction in the amplitude of chest wall motion by 
 1 90% from baseline over the previous 2 min for  1 10 s, and hypo-
pnea were defined as a reduction in the amplitude of chest wall 
motion by  1 50% from baseline over the previous 2 min for  1 10 s, 
associated with a  6 4% drop in oxygen saturation  [4] . In patients 
randomized to subtherapeutic CPAP, the subtherapeutic pressure 
was achieved by setting the CPAP machine to the lowest pressure, 
inserting a flow-restricting connector at the machine outlet, and 
inserting 6 extra holes in the collar of the main tubing at the end 
of the mask to allow air escape and to prevent rebreathing of car-
bon dioxide as previously described  [19] . Sleepiness was assessed 
using the Epworth sleepiness score (ESS)  [20] .
 Measurement of MPs 
 MPs were measured as previously described  [14] . Briefly, blood 
was drawn from fasting participants in the morning between
9: 00 and 10: 00 am. Within 1 min of venepuncture, the tubes were 
centrifuged at 1,550  g for 20 min to produce platelet-poor-plasma 
(PPP). Two hundred and fifty microliters of PPP were frozen im-
mediately and stored at –80  °  C. The 250   l PPP were thawed and 
then washed twice at 18,000  g for 30 min.
 CD31-phycoerythrin (PE) and CD41-phycoerythrin-Cy5 (PE-
Cy5) were used to differentiate between platelet-derived MPs 
(PMPs) CD31+CD41+ and endothelium-derived MPs (EMPs) 
CD31+CD41–. CD106-PE-Cy5 and CD62E-PE-Cy5 were also 
used as markers for EMPs. CD45-allophycocyanin (APC) was 
used as a marker for leukocyte-derived MPs (LMPs). CD66B-
FITC was used to stain granulocyte-derived MPs. All antibodies 
were supplied by BD, Oxford, UK.
 Appropriate PE, PE-Cy5, and APC isotypes were used as neg-
ative controls. Ten microliters of the sample were incubated with 
the appropriate MAbs for 30 min at room temperature, protected 
from light, followed by the addition of 900   l PBS-Ca. 
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 Samples were acquired using a BD FACSCalibur  (Becton 
Dickinson, Oxford, UK). The MP gate was checked with 1-  m 
beads (Sigma L-2778). The positivity gates were checked by fluo-
rescence-minus-one staining. MP analyses were performed blind 
to the patient’s group allocation.
 Data Analysis 
 Statistics were performed using GraphPad Prism 4 (GraphPad 
Software, USA) and SPSS Statistics 19 (IBM Software, USA). Dif-
ferences in baseline characteristics between groups were assessed 
by independent t tests and   2 tests as appropriate. Wilcoxon 
signed rank tests were performed to assess within-group changes. 
Comparisons of changes between groups were assessed by Mann-
Whitney U tests. Comparisons of changes between groups, cor-
rected for baseline levels of MPs, were analyzed by analysis of 
covariance (ANCOVA). Nonparametric confidence intervals 
were calculated using Confidence Interval Analysis Software 
(CIA version 1.1). p  ! 0.05 was considered statistically significant.
 Results 
 Subject Characteristics 
 Twenty subjects were randomly assigned to continue 
on therapeutic CPAP and 21 subjects were randomly as-
signed to receive subtherapeutic CPAP. One patient in 
the subtherapeutic CPAP group withdrew from the 
study 4 days after randomization because of intolerable 
daytime symptoms. In 2 patients from the subtherapeu-
tic CPAP group, blood could not be drawn at 2 weeks 
( fig. 1 ). There were no statistically significant differenc-
es in the baseline characteristics of the two groups ( ta-
ble 1 ).
43 patients eligible
2 patients did not attend
20 patients continued CPAP 21 patients received placebo-CPAP
Data of 20 patients analyzed Data of 18 patients analyzed
41 patients randomized 
1 patient
withdrew 
2 patients not
bled at 2 weeks 
110 patients assessed
67 did not enter the study:
– 51 did not consent  
– 11 did not meet inclusion criteria 
– 5 did meet exclusion criteria  
 Fig. 1. Trial profile. 
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 Sleep-Disordered Breathing and Sleepiness 
 Withdrawal of CPAP significantly increased the ap-
nea/hypopnea index (AHI) at 2 weeks (mean difference 
in AHI change +33.5; 95% CI +22.3 to +44.5) and the ODI 
(mean difference in ODI change +26.4; 95% CI +16.1 to 
+36.9) in comparison to continuation of CPAP (p  ! 0.001 
for all comparisons). ESS increased significantly at 2 
weeks in the subtherapeutic group compared to the ther-
apeutic group (mean difference in ESS change +2.7; 95% 
CI +1.1 to +4.3, p = 0.001) ( table 2 ). 
 Endothelium-Derived MPs 
 Withdrawal of CPAP therapy was associated with a 
significant increase in the number of both CD62E+ EMPs 
(p = 0.040) and CD106+ EMPs (p = 0.007) not seen in the 
therapeutic CPAP group ( fig. 2 ,  3 ). There was a significant 
difference in the change in CD62E+ EMP levels (median 
difference in change +32.4 per   l; 95% CI +7.3 to +64.1 
per   l, p = 0.010) ( fig. 2 c) between the therapeutic and 
subtherapeutic groups, and this level of significance was 
not altered when a correction for baseline levels of 
Table 1. B aseline patient characteristics
Therapeutic CPAP
group (n = 20)
Subtherapeutic CPAP 
group (n = 21)
p value
Age, years 63.6 (5.1) 61.8 (7.5) 0.393
Males/females 19/1 21/0 0.300
BMI 32.9 (6.5) 33.1 (4.4) 0.904
Waist/hip circumference ratio 1.0 (0.1) 1.0 (0.0) 0.106
Neck circumference, cm 46.4 (3.7) 46.1 (4.2) 0.838
Current smokers, % 19.1 5.0 0.170
Ex-smokers, % 38.1 25.0 0.368
Hypertension, % 80.9 70.0 0.414
Diabetes, % 23.8 20.0 0.768
CAD, % 4.8 10.0 0.520
Antihypertensive medication, % 76.2 65.0 0.431
Cholesterol-lowering medication, % 33.3 35.0 0.910
Glucose-lowering medication, % 9.5 15.0 0.592
Systolic blood pressure, mm Hg 133.3 (16.6) 129.2 (12.7) 0.380
Diastolic blood pressure, mm Hg 82.3 (7.8) 82.2 (8.2) 0.980
AHI original sleep study 36.0 (17.3) 45.3 (22.3) 0.155
ODI original sleep study 26.6 (13.5) 37.3 (22.7) 0.141
ODI 4-day withdrawal 25.4 (8.6) 28.9 (16.2) 0.401
AHI on CPAP 5.1 (2.7) 4.3 (2.3) 0.329
CPAP compliance, min 373.1 (67.9) 362.8 (72.3) 0.642
ESS before therapy 13.8 (2.6) 15.3 (3.5) 0.188
ESS on CPAP 7.4 (3.1) 6.6 (2.7) 0.399
V alues are means (SD) where applicable. AHI on CPAP = AHI downloaded from the CPAP machine averaged from the previous 6 
months.
Table 2.  Effect of CPAP withdrawal on sleep-disordered breathing and sleepiness
Baseline C hange from baseline 95% CI
between groups
p value
therapeutic
CPAP (n = 20)
subtherapeutic 
CPAP (n = 21)
therapeutic
CP AP (n = 20)
subtherapeutic 
CPAP (n = 20)
AHI, events/h 1.7 (1.8) 2.2 (2.5) +0.4 (2.8) +33.8 (24.3) +22.3 to +44.5 <0.001
ODI, events/h 0.5 (0.8) 0.9 (2.0) –0.2 (1.0) +26.3 (22.9) +16.1 to +36.9 <0.001
ESS 7.4 (3.1) 6.6 (2.7) –0.7 (2.2) +2.0 (2.7) +1.1 to +4.3 0.001
Val ues are means (SD). 
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CD62E+ EMPs was applied. There was no significant dif-
ference in the change in CD106+ EMPs levels (median 
difference in change +21.9 per   l; 95% CI –4.7 to +166.0 
per   l, p = 0.105) between the therapeutic and subthera-
peutic groups. Withdrawal of CPAP therapy did not sig-
nificantly change the number of CD31+CD41– EMPs 
(median difference in change –7.86 per   l; 95% CI –22.9 
to +10.8 per   l, p = 0.327) ( table 3 ).
 Granulocyte-Derived MPs (CD66B+) 
 Withdrawal of CPAP therapy was associated with a sig-
nificant increase in the number of CD66B+ granulocyte-
derived MPs (p = 0.029) not seen in the therapeutic CPAP 
group ( fig. 4 ). There was no significant difference in the 
change in CD66B+ MP levels between the therapeutic and 
subtherapeutic groups (median difference in change +16.3 
per   l; 95% CI –5.3 to +43.8 per   l, p = 0.132) ( table 3 ).
Baseline 2 weeks
0
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b Baseline 2 weeks
0
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*
–100 Therapeutic
CPAP
**
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CPAP
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h
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–50
0
c
50
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200
250
 Fig. 2. Median (IQR) levels of CD62E+ EMPs in OSA patients re-
ceiving either therapeutic ( a ) or subtherapeutic CPAP ( b ). In the 
subtherapeutic group there was a significant increase in CD62E+ 
EMPs (* p = 0.040) between baseline and 2 weeks not seen in the 
therapeutic group.  c Median (box: IQR, whiskers: range) change 
in CD62E+ EMPs between baseline and 2 weeks. There was a sig-
nificant difference (** p = 0.010) between the change in MP levels 
in the therapeutic and subtherapeutic groups.  
Baselinea 2 weeks
0
C
D
10
6+
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Ps
 p
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l
50
100
150
200
b Baseline 2 weeks
0
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 μ
l
50
100
150
200 **
 Fig. 3. Median (IQR) levels of CD106+ 
EMPs in OSA patients receiving either 
therapeutic ( a ) or subtherapeutic CPAP 
( b ). In the subtherapeutic group there was 
a significant increase in CD106+ EMPs
(** p = 0.007) between baseline and 2 
weeks not seen in the therapeutic group. 
Baselinea 2 weeks
0
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*
 Fig. 4. Median (IQR) levels of CD66B+ 
granulocyte-derived MPs in OSA patients 
receiving either therapeutic ( a ) or subther-
apeutic CPAP ( b ). In the subtherapeutic 
group there was a significant increase in 
CD66B+ granulocyte-derived MPs (* p = 
0.029) between baseline and 2 weeks not 
seen in the therapeutic group. 
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 Leukocyte-Derived MPs 
 Withdrawal of CPAP therapy did not significantly 
change the number of CD45+ LMPs, and there was no 
significant difference in the change in levels between the 
two groups (median difference in change –19.8 per   l; 
95% CI –45.5 to +10.7 per   l, p = 0.335) ( table 3 ).
 Platelet-Derived MPs 
 Withdrawal of CPAP therapy did not significantly 
change the number of PMPs, and there was no significant 
difference in the change in levels between the two groups 
(median difference in change +194 per   l; 95% CI –108
to +684 per   l, p = 0.193) ( table 3 ).
 Discussion 
 To our knowledge this is the first report of a random-
ized controlled trial investigating the effects of CPAP 
therapy on the level of MPs. Withdrawal of CPAP therapy 
for 2 weeks was associated with a significant increase in 
EMP levels, providing evidence that MP formation may 
be causally linked to OSA and may promote endothelial 
activation in these patients.
 Controlled trials have shown that OSA is an indepen-
dent causal factor for hypertension, and a risk factor for 
other cardiovascular diseases  [5, 21] , even when control-
ling for other risk factors. The current opinion is that the 
consequences of OSA, including intermittent hypoxia 
and intrathoracic pressure changes and arousals, may re-
sult in inflammation, endothelial dysfunction, and ulti-
mately arterial disease  [7] .
 MPs may provide a linking mechanism between OSA 
and cardiovascular disease. EMPs appear to be both a 
cause and a consequence of endothelial dysfunction, and 
levels are correlated with other markers of endothelial 
dysfunction  [22] . OSA is considered to represent a pro-
inflammatory state, demonstrated by increased levels of 
pro-inflammatory proteins and cytokines  [23, 24] . MPs 
can be produced in response to inflammation and they 
have potent pro-inflammatory potential. They can pro-
mote leukocyte aggregation and binding of monocytes to 
endothelial cells, an early step in vascular inflammation 
 [12] . MPs can also express phosphatidylserine and tissue 
factor, giving them thrombotic properties. Therefore, 
MPs have the potential to increase cardiovascular risk in 
OSA patients through endothelial dysfunction, inflam-
mation, and thrombosis. 
 In the current trial, CD62E+ EMPs and CD106+ EMPs 
were both significantly increased from baseline to 2 
weeks in the subtherapeutic group, and the change in 
CD62E+ EMP levels was significantly different between 
the therapeutic and the subtherapeutic groups. The base-
line CD62E+ EMP levels were not identical between the 
two groups, as may be expected in a randomized study. 
However, the significant difference in the change in 
CD62E+ EMP levels between the therapeutic and sub-
therapeutic groups held true, even when a correction for 
the baseline levels was applied. CD31+CD41– did not sig-
nificantly change over the 2 weeks in either patient group. 
It is recognized that subtypes of EMPs are formed by dif-
ferent mechanisms, and these subtypes express different 
markers. For example, CD62E+ EMPs are suggested to be 
markers of early endothelial cell activation, while raised 
numbers of CD31+CD41– EMPs are thought to reflect 
Table 3.  Effect of CPAP withdrawal on MP levels
Baseline C hange from baseline 95% CI
between
groups
p
value
therapeutic
CPAP (n = 20)
subtherapeutic
CPAP (n = 18)
therapeuti c
CPAP (n = 20)
subtherapeutic
CPAP (n = 18)
CD62E+ EMPs 36.8 (10.3 to 65.3) 16.2 (8.9 to 47.6) +1.7 (–16.4 to 8.7) +21.5 (–6.2 to 72.1) +7.3 to +64.1 0.010*
CD106+ EMPs 48.2 (16.9 to 125.8) 28.3 (12.8 to 49.3) +2.7 (–11.0 to 60.9) +20.9 (0.6 to 141.7) –4.7 to +166 0.105
CD31+CD41– EMPs 64.2 (49.0 to 94.6) 69.3 (17.5 to 112.7) –1.3 (–28.9 to 20.3) +7.5 (–18.3 to 64.8) –22.9 to +10.8 0.327
CD66B+ granulocyte MPs 23.8 (14.4 to 43.6) 27.0 (16.5 to 37.9) +2.1 (–21.4 to 20.1) +8.1 (–4.7 to 46.5) –5.3 to +43.8 0.132
CD45+ LMPs 84.9 (18.6 to 160) 59.3 (4.8 to 200) –1.3 (–9.6 to 28.7) –5.2 (–57.8 to 10.0) –45.5 to +10.7 0.335
CD31+CD41+ PMPs 530 (322 to 965) 534 (370 to 1561) –75 (–489 to 205) –8.5 (–78.0 to 690) –108 to +684 0.193
Val ues are medians (IQR) per l. * p < 0.05.
p values were calculated by a Mann-Whitney test of change from baseline between the therapeutic CPAP and subtherapeutic CPAP groups.
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structural damage of endothelial cells  [25] . Therefore, the 
findings of this study suggest that EMPs produced during 
cell activation are affected by CPAP therapy; however, 
those produced during cell death are not. We previously 
reported that EMPs were not elevated in a group of min-
imally symptomatic OSA patients compared to matched 
controls  [14] ; however, only CD31+CD41– EMPs were ex-
amined.
 Yun et al.  [16] reported significantly higher levels of 
EMPs in OSA than in matched controls and that EMPs 
were correlated with OSA severity. Following CPAP 
treatment, a significant reduction in CD62E+ EMPs, but 
not CD31+CD42– EMPs, was found. These findings were 
also corroborated by Jelic et al.  [15] , who reported elevat-
ed levels of EMPs in OSA patients and a trend towards 
decreased levels following CPAP, in a treatment uncon-
trolled study. CPAP treatment has previously been shown 
to improve endothelial function  [8, 9] , and indeed in the 
current trial a deterioration in endothelial function fol-
lowing CPAP therapy withdrawal was observed  [18] . 
Therefore, the decrease in EMP levels with CPAP therapy 
may be an underlying mechanism of endothelial function 
improvement. However, it is remains unclear whether 
EMPs are a cause or a consequence of endothelial dys-
function. This uncertainty will need to be addressed in 
future studies.
 Withdrawal of CPAP therapy was associated with a 
significant increase in the number of granulocyte-de-
rived MPs. However, there was no significant difference 
in the change in levels between groups. Priou et al.  [26] 
found that granulocyte-derived MPs were increased in 
OSA patients, with an ODI of  6 10 events per hour. Poly-
morphonuclear cells have an enhanced readiness to re-
spond with superoxide generation in OSA, which is
reversed by CPAP treatment  [27] . Therefore, it may be 
expected that granulocyte-derived MPs, a marker of 
polymorphonuclear cell activation, would be significant-
ly elevated following withdrawal from CPAP.
 Withdrawal of CPAP therapy was not associated with 
a significant change in the number of LMPs in the cur-
rent study, even though LMPs have previously been 
shown to be elevated in OSA  [14] . An explanation for this 
unexpected finding may be that 2 weeks of CPAP with-
drawal was not long enough to cause a significant in-
crease in LMPs.
 PMP levels have also previously been shown to be el-
evated in patients with minimally symptomatic OSA  [14] . 
Thus it may be expected that a treatment which signifi-
cantly improves the pathophysiological consequences 
and symptoms of OSA may also reduce the levels of PMPs. 
However, levels of PMPs were not significantly changed 
from baseline over the 2 weeks in either patient group. It 
may be the case that 2 weeks of treatment withdrawal is 
not sufficient to increase the levels of PMPs. 
 Limitations 
 We cannot exclude that a longer CPAP withdrawal pe-
riod would be associated with more pronounced changes 
in MP levels; however, because of ethical issues, it may be 
difficult to prolong the intervention time. Short-term 
CPAP withdrawal may also have an exaggerated detri-
mental effect, as OSA patients on therapy may lose adap-
tive mechanisms to cope with endothelial damage. While 
flow cytometry is a commonly used method for MP anal-
ysis, it cannot be used to detect MPs smaller than 300 nm 
in diameter  [28, 29] , depending on the threshold of the 
machine.
 Conclusions 
 This is the first randomized controlled trial to assess 
the impact of CPAP therapy withdrawal on MP levels. 
Withdrawal of CPAP therapy for 2 weeks was associated 
with a significant increase in EMPs. These results provide 
evidence that MP formation may be causally linked to 
OSA and may promote endothelial activation in these pa-
tients.
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